Background : Non-vitamin K antagonist oral anticoagulants (NOACs)show a favorable balance between efficacy and safety compared to warfarin in patients with non-valvular atrial fibrillation(NVAF). NOACs are mainly or partially eliminated by the kidneys. The aim of this study was to evaluate the influence of renal function on treatment persistence with NOACs and to compare NOAC and warfarin treatments in Japanese NVAF patients. Methods : We retrospectively studied 819 NVAF patients who newly started NOACs during the first 24 months after our hospital adopted the use of these drugs(249 patients treated with dabigatran, 156 with rivaroxaban, and 202 with apixaban)and 212 NVAF patients who newly started warfarin during the same period. Impaired renal function was defined as a decrease in creatinine clearance(CrCl)to below 50 mL／min. The endpoint was discontinuation of each drug. Results : During the follow-up period, 139(23％)patients who newly started NOACs and 22(10％)patients who newly started warfarin discontinued the drug. The patients who were prescribed NOACs were less likely to continue treatment than those who were prescribed warfarin. Among patients with CrCl ＜50 mL／min, those who were prescribed NOACs had lower 12-month persistence rates (dabigatran, 47.4％ ; rivaroxaban 63.2％ ; apixaban, 80.6％ ; and warfarin, 98.2％) than those who were prescribed warfarin. The most common reason for discontinuation was the occurrence of adverse events including gastrointestinal symptoms and bleeding. Conclusions : Our study showed a significantly lower persistent rate in NVAF patients who were prescribed NOACs compared to patients who were prescribed warfarin, especially among the patients with CrCl below 50 mL／min.
Introduction
Atrial fibrillation (AF) is the most clinically prevalent type of tachyarrhythmia 1, 2) and is a potential risk factor for stroke 3, 4) . Anticoagulant therapy with the vitamin K antagonist warfarin reduces the risk of AF-related stroke 4, 5) . Recently, several nonvitamin K antagonist oral anticoagulants (NOACs) have been developed. Landmark phase 3 randomized clinical trials(RCTs) ［the Randomized Evaluation of Long-Term Anticoagulation Therapy(RE-LY)trial 6) , the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) 7) , the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation(ARISTO-TLE)trial 8) , and the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48(ENGAGE AF-TIMI 48)trial 9) ］have demonstrated that NOACs are at least as safe and effective as warfarin in preventing stroke／systemic embolisms in non-valvular AF (NVAF)patients 6−10) . NOACs are mainly or partially eliminated by the kidneys(dabigatran, 80％ ; rivaroxaban, 33％ ; apixaban, 25％ ; and edoxaban, 50％), and their blood drug concentrations in patients with renal impairment are higher than in subjects with normal renal function 11−14) . Patients with creatinine clearance (CrCl)＜30 mL／min(＜25 mL／min in the ARISTOTLE trial) were excluded from phase 3 RCTs 6−9) . In a sub-analysis of the RE-LY trial, ischemic stroke and bleeding outcomes correlated with dabigatran plasma concentrations 15) . Therefore, the individual treatment benefits of NOACs, especially those with high renal excretion ratios, may be influenced by an individual patientʼs renal function.
In the real-world setting, adequate treatment persistence with the appropriate anticoagulation drugs is important for the prevention of stroke among at-risk NVAF patients. In a previous study, we reported a significantly lower persistence rate of prescribed NOACs within one year of treatment initiation compared to prescribed warfarin in Japanese patients with NVAF 16� . In that study, adverse event related to the treatment was one of the causes of treatment discontinuation 16� . The aim of the present study was to evaluate the effect of renal function on the persistence of NOAC treatment and to compare NOAC and warfarin treatments in a sample of Japanese NVAF patients.
Methods

Subjects
We conducted a retrospective cohort study of NVAF patients who newly started NOACs as long-term anticoagulation therapy during the first 24 months after our hospital adopted the use of these new drugs. To identify patients who were prescribed NOACs and warfarin, we first searched the automated prescription databases. Then, we confirmed each patientʼs diagnosis of AF by checking their medical records. We excluded patients with valvular heart disease, concurrent hyperthyroidism, or hemodialysis, and patients without risk factors for stroke. Valvular heart disease was defined as moderate or severe mitral stenosis and mild rheumatic mitral stenosis based on angiographic, hemodynamic or echocardiographic results, or a history of valvular surgery including valvular repair or replacement. We also excluded patients who transiently used anticoagulants for cardioversion or catheter ablation and who did not visit our clinic after they were newly prescribed anticoagulants.
This study was approved by the Institutional Review Board of Tokyo Womenʼs Medical University �approval number : 2887-R2�.
Clinical characteristics
Data on patientsʼ age, sex, traditional stroke risk factors such as hypertension and diabetes, underlying diseases, and concomitant medications were obtained from medical records and laboratory data. Creatinine clearance was calculated using the CockcroftGault formula 17� . Impaired renal function was defined as a decrease in CrCl to below 50 mL／min. Hypertension was defined as a systolic blood pressure B140 mmHg, a diastolic blood pressure B90 mmHg, or a history of treatment for hypertension. Diabetes mellitus previously diagnosed by a physician was defined as treatment with hypoglycemic agents or was indicated by poor glycemic control�defined as a glycohemoglobin A1c B6.5％�. Coronary artery disease was diagnosed based on positive stress test results, coronary angiography demonstrating at least 75％ stenosis or coronary spastic angina documented by an acetylcholine provocation test, a history of prior myocardial infarction, or a history of revascularization procedures. Heart failure was defined according to the American College of Cardiology／American Heart Association criteria 18� ; the patients in our study were identified as having either stage C �current or prior symptoms of heart failure�or stage D�refractory heart failure�heart failure.
The CHADS2 ［Congestive heart failure, Hypertension, Age B 75, Diabetes, Stroke�doubled�］score and the CHA2DS2-VASc ［Congestive heart failure／left ventricular dysfunction, Hypertension, Age B75�doubled�, Diabetes, Stroke�doubled�-Vascular disease, Age 65-74, and Sex category�female�］score were used to calculate stroke risk.
Follow-up
Follow-up data were obtained at routine or extra visits at our institution. The patients were followed until the end of the follow-up period�25 months after the adaption of each drug : until April 2013 for dabigatran and warfarin ; until June 2014 for rivaroxaban ; and until April 2015 for apixaban� or until they discontinued treatment, ceased with follow-up, or died. Information concerning deceased patients was obtained from the medical records, family members, patientsʼ general practitioners, and hospitals to which they had been admitted. For the patients who started warfarin, we also collected prothrombin timeinternational normalized ratio�PT-INR�data.
Outcomes
Discontinuation of each drug was defined as the discontinuation of drug prescription and physicianʼs mention of drug discontinuation in the medical record. All drug discontinuations were reviewed in the medical records, and the reasons for discontinuation were also obtained. Temporary discontinuation for specific reasons such as surgery was not considered to be therapy cessation. The occurrence of thromboembolic and bleeding events was validated through a medical records review by 3 investigators �M. N., T. S. and T. N.�. The thromboembolic events included fatal or nonfatal ischemic strokes, transient ischemic attack�TIA�, and other systemic embolisms. Ischemic stroke was defined as sudden onset of a new focal neurological deficit that lasted more than 24 h and could not be explained by other causes. Patients were diagnosed with TIA when the neurological deficit lasted less than 24 h. Computed tomography or magnetic resonance imaging was performed on all patients. Other systemic embolisms were diagnosed using computed tomography, angiography or thrombectomy, and diagnosis was based on the absence of underlying atherosclerosis in the affected artery. Major bleeding events were defined as follows : fatal bleeding ; symptomatic bleeding in a critical area or organ, such as intracranial, gastrointestinal and other types of bleeding that required endoscopic hemostasis, surgical intervention or hospital admission ; and bleeding that caused a decrease in hemoglobin level of 2 g／dL or more or led to a blood transfusion. For patients who were admitted to other hospitals due to adverse events and thus were not subsequently observed at our hospital, information was obtained from the respective hospitals. A neurologist�T. N.�also reconfirmed the stroke, TIA and intracranial hemorrhage diagnoses in these patients.
Statistical analysis
Summary data are presented either as median and range, or as number of patients. Patients were divided into CrCl B50 and CrCl ＜50 mL／min. For each CrCl level, baseline clinical data were compared between each NOAC and warfarin using Wilcoxon rank sum test. Categorical variables were analyzed with chi-square test. P values ＜0.05 were considered significant. Time in the therapeutic range�TTR�was calculated using the
Rosendaal linear interpolation method 19)
. This method is a linear interpolation of consecutive PT-INR values, and calculates the percentage of time that PT-INR is below, within or above the therapeutic range(1.60 to 2.59), which is based on the target PT-INR for low intensity in Japanese clinical practice 20−22) . The cumulative persistence rates of the prescribed drugs were calculated using the Kaplan-Meier method. The differences in persistence rate were compared using log rank test. The hazard ratio of discontinuation for each of the NOACs versus warfarin during the follow-up period was calculated using Cox proportional hazard model. Problems of multiple comparisons were counteracted by Bonferroni correction, giving an adjusted significance level of P ＜0.0083. Data analyses were performed using JMP11 statistical software (version 11.2, SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
The patientsʼ baseline characteristics are shown in Table 1 . Among patients with CrCl B50 mL／min, the patients who were prescribed NOACs were older than those who were prescribed warfarin. Among patients with CrCl ＜50 mL／min, however, there were no differences in age and gender ratio across treatment groups. The proportion of patients who had previous stroke／TIA was higher in the dabigatran group than in the warfarin group. The distribution of CHADS2 scores did not differ between each of the NOACs and warfarin, but the proportion of CHA2DS2-VASc score B4 was higher in the dabigatran group among patients with CrCl B50 mL／min. The distribution of NOAC-and warfarin-treated patients did not differ when stratified by CrCl (Figure 1 ). Among patients with CrCl B50 mL／min, the proportions of low-dose dabigatran(220 mg／day), rivaroxaban (10 mg／day) and apixaban (5 mg／day) were high. All patients with CrCl B50 mL／min who received 10 mg／day of apixaban did not meet the criteria for dose reduction.
Persistence of NOAC and warfarin therapies
During the follow-up period, 139(23％)of 607 patients who had newly started NOACs and 22(10％)of 212 patients who had newly started warfarin discontinued the respective drug. The Kaplan-Meier curves for the persistence rates of NOACs and warfarin are shown in Figure 2 . The patients who were prescribed NOACs were less likely to continue with treatment than those who were prescribed warfarin. Among patients with CrCl ＜50 mL／min, the patients who were prescribed NOACs had lower 12-month persistence rates than those who were prescribed warfarin. As Figure 3 shows, the patients who were prescribed each NOAC were less likely to continue with NAGANUMA M, et al. : Renal Function 
treatment than the patients who were prescribed warfarin. Among patients with CrCl ＜50 mL／min, the patients who were prescribed each NOAC had lower 12-month persistence rate �dabigatran, 47.4％ ; rivaroxaban 63.2％ ; apixaban, 80.6％ ; and warfarin, 98.2％)than those who were prescribed warfarin. Among patients with CrCl ＜50 mL／min, the treatment discontinuation rate during the follow-up period was higher as the renal excretion ratio of NOAC increased�Table 2).
Discontinuation of drugs and reasons for discontinuation
The occurrence of adverse events including gastrointestinal symptoms, bleeding, and abnormal laboratory data during anticoagulant therapy was the most common reason for discontinuing NOAC treatment �Table 3). The majority of abnormal laboratory data were elevated transaminases and prolonged activated partial thromboplastin time �＞2 × upper limit of normal). Among the patients taking dabigatran, which is highly excreted by the kidneys, worsened renal function was also an important reason, especially in those with CrCl ＜50 mL／min. Patient desire such as not wanting to take the prescribed anticoagulant drug was also a common reason. Other reasons included the cost, number of doses, prescription period limited to 2 weeks�one year after approval in Japan), and switching from NOACs to warfarin or vice versa for surgical／interventional procedures�Table 3). The patients who were prescribed warfarin had a lower rate of discontinuation due to adverse events than those who were prescribed NOACs, and the patients with CrCl ＜ 50 mL／min who were prescribed NOACs had higher 12-month discontinuation rates�dabigatran, 39.2％ ; rivaroxaban 22.7％ ; apixaban, 16.0％ ; and warfarin, 1.8％)than those with CrCl ＜ 50 mL／min who were prescribed warfarin. Among patients with CrCl ＜50 mL／min, the treatment discontinuation rate due to adverse events during the follow-up period was also higher as the renal excretion ratio of NOAC increased�Table 4).
Outcomes
The mean TTR was 52％ during the initiation and maintenance phases of warfarin therapy. The incidence of thromboembolic and major bleeding events was not noticeably different between the patients prescribed NOACs and those prescribed warfarin regardless of CrCl level�Table 5).
Antithrombotic treatment after discontinuation of the initially prescribed NOAC or warfarin is shown in Table 6 . One-half of the patients who discontinued NOACs received warfarin, and one-fifth of the patients received other NOACs. One-half of the patients who discontinued warfarin received NOACs. However, one-fourth of the patients who discontinued NOACs or warfarin did not receive any subsequent antithrombotic therapy. One patient who discontinued apixaban due to gastrointestinal bleeding experienced stroke on the following day and another patient who changed from dabigatran to warfarin died from stroke.
Discussion
Our study of NVAF patients who newly started treatment with NOACs or warfarin revealed the following findings : 1) the patients who were prescribed NOACs were less likely to continue with treatment than the patients who were prescribed warfarin ; 2)among patients with CrCl ＜50 mL／min, those who were prescribed NOACs had lower treatment persistence rates than those who were prescribed warfarin ; 3)the most common Renal excretion ratio；dabigatran 80％, rivaroxaban 33％, apixaban 25％, and warfarin ＜1％ CI, confidence interval；CrCl, creatinine clearance；HR, hazard ratio；NOACs, non-vitamin K oral anticoagulants ＊ p＜0.0083 compared to warfarin after Bonferroni correction.
Drug Table 2 Hazard ratio of discontinuation for each of the NOACs versus warfarin Renal excretion ratio；dabigatran 80％, rivaroxaban 33％, apixaban 25％, and warfarin ＜1％. CI, confidence interval；CrCl, creatinine clearance；HR, hazard ratio；NOACs, non-vitamin K oral anticoagulants ＊ p＜0.0083 compared to warfarin after Bonferroni correction.
Drug
Table 4
Hazard ratio of discontinuation due to adverse events for each of the NOACs versus warfarin Table 3 Discontinuation of drugs and causes of cessation
reason for treatment discontinuation was the occurrence of adverse events including gastrointestinal symptoms and bleeding ; 4)among patients with CrCl ＜50 mL／min, the treatment discontinuation rate, including discontinuation due to adverse events, was higher as renal excretion ratio of NOAC increased.
Persistence of NOAC and warfarin therapies
As reported in our previous study, NOAC treatment persistence rate was significantly lower compared to warfarin treatment persistence rate in Japanese patients with AF 16) . A meta-analysis of RCTs reported that the discontinuation rates of NOACs, warfarin and aspirin for the prevention of stroke in AF patients were not significantly different 23) . A cohort study of NVAF patients in the US found that the persistence rate in patients who were prescribed warfarin was lower than that in patients who were prescribed dabigatran 24) . The 12-month persistence rate for dabigatran in the above cohort was 63.3％, and 12-month persistence rates for dabigatran and rivaroxaban of approximately 75％ and 85％, respectively were reported for a cohort of patients in Dresden 24−26) . The persistence rates for NOACs in our study�dabigatran, 66.0％ ; rivaroxaban, 65.7％ ; and apixaban, 81.4％)are comparable to previous results, but the persistence rate for warfarin�88.4％)in our study was higher than those in US cohort studies 24,27−30) . Although the reason for this difference is unclear, it might be partially due to differences in the medical care systems�such as the number of regular cardiology visits in outpatient clinics and the improvement of patient adherence to warfarin use by frequent PT-INR monitoring and dose adjustment) 16) . This may also mean that TTR is generally higher in Japan than in other countries 22, 31) . Previous Japanese guideline for pharmacotherapy of AF �JCS 2008) recommended INR monitoring at least weekly during the period of induction of warfarin therapy and at least monthly after achieving a stable INR �class Ⅰ) 32) . Therefore, Japanese physicians usually perform PT-INR measurement and dose adjustment frequently, which leads to high TTR. These actions may enhance patientʼs awareness of the anticoagulation therapy and adherence to warfarin therapy.
The most common reason for NOAC treatment discontinuation was the occurrence of adverse events including bleeding events, similar to the Dresden cohort 25, 26) .
Renal function and persistence of NOAC therapy
In patients with CrCl ＜50 mL／min, a more clearly observable difference was found between the persistence rates for prescribed NOACs and that for warfarin. The patients with CrCl ＜50 mL／ min were older and had higher CHADS2 scores compared to the patients with CrCl B50 mL／min. In our study, the discontinuation rate increased with increase in renal excretion ratio of NOAC among patients with CrCl ＜50 mL／min. This tendency was also observed in discontinuation of treatment due to adverse events, which was the most common reason for stopping treatment. Direct inhibition of thrombin or activated factor Xa by NOACs is dose-dependent, and bleeding events have been found to be somewhat dose／concentration-dependent 15, 33) . The plasma drug concentration may be higher in patients with CrCl ＜50 mL／min who were prescribed NOACs that are mainly or partially eliminated by the kidneys. Although we did not obtain data on plasma drug concentration, the fact that the discontinuation rate was higher as renal excretion ratio of NOAC increased �dabigatran ＞ rivaroxaban ＞ apixaban) partially supports this hypothesis. However, the persistence rate for warfarin was not influenced by renal function because warfarin is mainly Table 6 Antithrombotic treatment after discontinuation of each NOAC and warfarin
metabolized by the liver. In our study, the occurrence of adverse events including bleeding events was the major cause of treatment discontinuation. Japanese patients dislike having side effects from drugs, even though they are mild, and patient preference may be an important factor for adherence to anticoagulation therapy and treatment persistence. We found no clear relationship between renal function and other reasons of treatment discontinuation.
In interpreting our results, the time of drug approval for each NOAC should be considered. In Japan, dabigatran was first approved as a NOAC in January 2011, and rivaroxaban and apixaban were approved later(in January and December 2012, respectively). Many physicians have improved their clinical skills in patient care and management of NOAC therapy over the past 4 years after dabigatran was approved. This issue may also contribute to treatment persistence.
Outcomes
The incidence of thromboembolic and bleeding events was low in both patients who were prescribed NOACs and those who were prescribed warfarin. In the RE-LY trial, patients with moderate renal function showed a 2.3-fold increase in the steady-state trough concentration of dabigatran compared with those with normal renal function. However, NVAF patients with moderate renal function showed a reduction in strokes with dabigatran treatment compared with warfarin treatment, and the risk of major bleeding was comparable to that of warfarin 34) . Subanalyses of the ROCKET AF and ARISTOTLE trials also indicated that rivaroxaban and apixaban did not increase the risk of major bleeding(including intracranial hemorrhage)in NVAF patients with moderate renal impairment 35, 36) . In anticoagulation therapy, minor bleeding is commonly observed but does not lead to the occurrence of severe or serious major bleeding 37) . The decision to continue or discontinue anticoagulant should be made after careful evaluation of the risks and benefits of continuing and discontinuing the drug.
Limitations
This study features certain limitations. First, the study is a retrospective observational study with a small sample size and includes treatment selection bias. The different data sampling times might affect the results in this study. Second, this was a cohort study at a single center. The clinical characteristics of our patients might not represent the general NVAF patients in Japan because our institution is a university hospital. Third, we were not able to detect all minor adverse events. To confirm the effect of renal function on NOAC treatment persistence, additional well controlled prospective cohort studies are necessary.
Conclusion
Our retrospective study showed a significantly higher discontinuation rate in NVAF patients who were prescribed NOACs compared to those who were prescribed warfarin, especially among patients with CrCl ＜50 mL／min. Renal impairment may limit NOAC treatment persistence in NVAF patients.
